What You Should Know:
– Define Ventures, a prominent venture capital firm specializing in early-stage health tech companies, has announced the addition of Carolyn Magill as a venture partner.
– Magill, a seasoned healthcare executive with 25 years of experience, will leverage her expertise to support Define Ventures’ portfolio companies in scaling and achieving category-defining status.
Magill Bio/Background
Magill brings a wealth of experience to Define Ventures, having held executive leadership positions across payer, provider, and pharmaceutical organizations. Most recently, she served as CEO of Aetion, a platform that transforms real-world data into regulatory-grade evidence for critical healthcare decisions. rior to Aetion, Magill was CEO of Remedy Partners, a leading bundled payments software and services company. She also served as Executive Vice President of Payer Strategy and Operations at Evolent Health, playing a key role in the company’s growth from startup to IPO. Additionally, she held several leadership roles at UnitedHealth Group, including Chief Operating Officer of its Community and State plan in New Jersey.
Define Ventures Background
Define Ventures, with $800M in assets under management, focuses on partnering with companies at the seed, Series A, and Series B stages. The firm is known for its high-conviction approach and has partnered with over two dozen companies, including Hims & Hers (NYSE: HIMS), Unite Us, and Cohere Health.
